Once again, there was a clear reduction in the CD200R-staining MFI in all anti-CD200R antibody-treated tumours (Supplementary Fig. S2D), indicating that the antibody was successfully binding to immune cells in the tumour. This evidence concerns the gene CD200R1 and neoplasm.